Moleculin Biotech reports Q3 EPS ($2.85) vs. ($2.82) last year

As of September 30, 2024, the company had cash and cash equivalents of $9.4M and believes that the existing cash and cash equivalents as of September 30, 2024, will be sufficient to fund planned operations into Q1 2025. “We are thrilled to have emerged as a late stage company. Our focus remains on the ramp up for and execution of our upcoming MIRACLE trial. We have been extremely active and our recent interactions with potential clinical trial sites globally have been overwhelmingly positive as we prepare for the start of enrollment and dosing early next year. We believe with our recent clinical and regulatory ‘wins,’ we have foundationally set the stage for a transformational year ahead and the opportunity to drive significant value for all stakeholders. With that said, we continue to follow our CRc (complete response composite) preliminary data from our MB-106 Phase 1B/2 AML clinical trial. We are also pleased with the median durability continuing to climb – and is now in excess of 8 months,” commented CEO Walter Klemp.